5 July 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2024 PBAC meeting are now available.

The MAESTrO Database has been updated accordingly (addition of (missing) information on patient populations, outcomes, comparators, clinical trials, type of economic evaluation, primary outcome, risk sharing agreement, link to Public Summary Document).

Insights will be added in the coming days. The team has already identified the following insights:

• The PBAC recommended the PBS listing of cabozantinib maleate for the treatment of patients with locally advanced or metastatic differentiated thyroid cancer who are radioactive iodine refractory or ineligible, that has progressed following treatment with a tyrosine kinase inhibitor or have developed intolerance to prior VEGF targeted therapy. The PBAC recommended a price reduction so that the resulting ICER was less than $95,000 - $115,000/QALY gained.
• The PBAC recommended the PBS (Authority Required) listing of selumetinib sulphate for the treatment of children/adolescents with symptomatic inoperable plexiform neurofibroma(s) with NF1. the PBAC considered that selumetinib sulphate would be cost effective at an ICER of no more than $135,000 - $155,000/QALY gained.

Read PBS News